BridgeBio Oncology initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Robert Burns initiated coverage of BridgeBio Oncology (BBOT) with a Buy rating and $27 price target BridgeBio is a clinical stage biotechnology company developing next-generation inhibitors that are designed to provide cancer patients with significant benefit over standard-of-care treatments, the analyst tells investors in a research note.